Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 10, 2022
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
Thomas Williams, Carmen Tur, Arman Eshaghi, et al.
Trials
|
August 9, 2022
Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials
Thomas Williams, Sarah Alexander, James Blackstone, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 29, 2014
Plasma melatonin is reduced in Huntington's disease
Eirini Kalliolia, Edina Silajdžić, Rajasree Nambron, et al.
The Lancet. Neurology
|
May 30, 2020
MS-SMART study: systematic sampling bias concerns - Authors' reply
Jeremy Chataway, Floriana De Angelis, Peter Connick, et al.
European Journal of Neurology
|
February 10, 2026
Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis
Nevin A John, Yingtong Li, Floriana De Angelis, et al.
European Journal of Neurology
|
July 9, 2025
Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 Cohort
Charles Wade, Anisha Doshi, Sean Apap Mangion, et al.
Multiple Sclerosis and Related Disorders
|
February 8, 2025
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS
Anisha Doshi, Nils Muhlert, Gloria Castellazzi, et al.
Practical Neurology
|
November 12, 2024
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance
Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, et al.
European Journal of Neurology
|
December 18, 2024
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis
Nevin A John, Yingtong Li, Floriana De Angelis, et al.
Multiple Sclerosis and Related Disorders
|
November 23, 2024
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty
Tarunya Arun, Kate Petheram, Emma Tallantyre, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 10, 2022
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
Thomas Williams, Carmen Tur, Arman Eshaghi, et al.
Trials
|
August 9, 2022
Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials
Thomas Williams, Sarah Alexander, James Blackstone, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 29, 2014
Plasma melatonin is reduced in Huntington's disease
Eirini Kalliolia, Edina Silajdžić, Rajasree Nambron, et al.
The Lancet. Neurology
|
May 30, 2020
MS-SMART study: systematic sampling bias concerns - Authors' reply
Jeremy Chataway, Floriana De Angelis, Peter Connick, et al.
European Journal of Neurology
|
February 10, 2026
Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis
Nevin A John, Yingtong Li, Floriana De Angelis, et al.
European Journal of Neurology
|
July 9, 2025
Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 Cohort
Charles Wade, Anisha Doshi, Sean Apap Mangion, et al.
Multiple Sclerosis and Related Disorders
|
February 8, 2025
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS
Anisha Doshi, Nils Muhlert, Gloria Castellazzi, et al.
Practical Neurology
|
November 12, 2024
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance
Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, et al.
European Journal of Neurology
|
December 18, 2024
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis
Nevin A John, Yingtong Li, Floriana De Angelis, et al.
Multiple Sclerosis and Related Disorders
|
November 23, 2024
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty
Tarunya Arun, Kate Petheram, Emma Tallantyre, et al.
Page
of 4